Active	Status	Sponsor type	Region	Phase	Filter
6 Active 0 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Dukes, Reagan
NCT06427395: Open-Label Extension Study of Saroglitazar Magnesium in Participants with Primary Biliary Cholangitis	Recruiting	3	150	US, RoW	Saroglitazar Magnesium 1 mg	Zydus Therapeutics Inc.	Primary Biliary Cholangitis	04/27	07/27
NCT05104853: Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects with Primary Biliary Cholangitis	Active, not recruiting	1/2	42	US	CNP-104, Placebo	COUR Pharmaceutical Development Company, Inc.	Primary Biliary Cholangitis	01/26	01/26
NCT04826224: CAM Procedure with BMAC for Shoulder OA	Recruiting	1	12	US	Concentrated bone marrow aspirate administration after Comprehensive Arthroscopic Management (CAM) surgical procedure.	Shane A. Shapiro	Shoulder Osteoarthritis	06/25	06/25
NCT05354544: Evaluating Autologous Stromal Vascular Fraction in Subjects with Vocal Fold Scar	Terminated	1	2	US	Autologous adipose derived SVF	Shane A. Shapiro	Vocal Fold Scars	12/24	12/24
NCT04392206: AMSC for Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses	Recruiting	1	15	US	Adipose Derived Mesenchymal Stem Cells, AMSC	Houssam Farres, M.D.	End Stage Renal Disease	06/25	06/25
Klosowski, Angelica
EPICS-III, NCT05133336 / 2022-001634-10: Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis	Active, not recruiting	2/3	186	NA	Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Placebo	Zydus Therapeutics Inc., Zydus Therapeutics Inc.	Primary Biliary Cholangitis	05/25	05/25